Monday morning snapshot

A snapshot of the early morning's equity news and key market movements.

Friday night in the US: The Dow Jones closed up 30.8 points at 16,452, the NASDAQ finished down 15.9 points at 4336.22 and the S&P 500 ended the day up one point at 1878.04, a closing high, but below the intraday peak of 1883.5.  

This morning in London: The FTSE 100 is currently down ten points at 6702.

FX and commodities: GBP/USD is down 15 pips at $1.6696, EUR/USD is up nine pips at $1.3664 and USD/JPY is down 16 pips at ¥103.1. Brent crude is up 91.5 cents at $108.06 and gold is trading at $1334, down $5.88.

Stocks: GlaxoSmithKline, the pharma giant, has reported that it has boosted its stake in its Indian subsidiary, to 75% from 50.7%, and the shares are up 0.45% so far, at £16.61. FTSE 250 manufacturing firm Senior has acquired rival firm Upeca Technologies for £75.5 million and the shares are 1.3% higher at 294.4p. In 2014 so far, the best performer has been Randgold Resources, up around 28%, while Aberdeen Asset Management takes the wooden spoon, having lost around 23% since 1 January.

The day ahead: Having had weaker Chinese CPI figures over the weekend (with price growth in February being 2% rather than the forecast 2.1%), we are now awaiting the eurozone sentix investor confidence report for March at 9.30am, then Canadian housing starts at 12.15pm. Economic data is light today, but regional Federal Reserve president Charles Plosser will speak in Paris at 10.15am.

All figures correct at 8.15am. All times London time.

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.